We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for tozinameran and famtozinameran (Pfizer Australia Pty Ltd)
Active ingredients
tozinameran and famtozinameran
Sponsor
Date of review outcome
Lapse date
Type
Provisional determination
Indication
As a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 months to < 5 years of age
Therapeutic area
Infectious diseases